Researchers Identify Specific Lung Cancer Susceptibility GeneApril 16, 2009Cincinnati - University of Cincinnati (UC) cancer cell biologists have identified a distinct gene linked to increased lung cancer susceptibility and development. They say this gene--known as RGS17--could result in a genetic predisposition to develop lung cancer for people with a strong family history of the disease. With further investigation, they believe the gene could be used to identify high-risk patients who may benefit from earlier, more aggressive lung cancer screening. Marshall Anderson, PhD, and his colleagues report their findings in the April 15, 2009, issue of the journal Clinical Cancer Research. "Understanding how the RGS17 gene impacts cancer development could change clinical diagnosis and treatment as radically as discovery of the breast cancer genes (BRCA1 and BRCA2) did,"¯ explains Anderson, who has led the multi-institutional Genetic Epidemiology of Lung Cancer Consortium (GELCC) studying the genetic basis of lung cancer since 1997. "A proven genetic test could help us identify people at risk before the disease progresses."¯ According to the American Cancer Society, lung cancer is the leading cause of cancer related disease and death. Although tobacco smoke is the primary environmental cause of the disease, science has shown there is also a strong genetic component to the disease. "This study represents a significant contribution to our understanding of lung cancer susceptibility and is another step toward to the goal of preventive medicine,"¯ says David Christiani, MD, MPH, a professor of occupational medicine and environmental health at the Harvard School of Public Health, whose two-page commentary on the study is published in conjunction with the GELCC team's scientific findings. "The authors undertook a daunting challenge of performing a family-based study of lung cancer in an effort to identify specific causal genes."¯ Genes, which are located in fixed positions on the cell's chromosomes, carry the DNA code that determines inherited characteristics, including a risk of certain diseases. For this study, Anderson and his multi-institutional team collected biological samples from numerous multigenerational families with five or more members who were affected by lung cancer. Through a combination of what is known as "fine mapping"¯--where genetic information is dissected and analyzed--and genetic association studies, researchers identified RGS17 as a major candidate susceptibility gene for familial lung cancers. Research has shown that lung cancer can occur sporadically--where people have no known risk factors or family history--or hereditarily, occurring in multiple members of the same family. In 2004, Anderson's team reported the first genetic evidence of a major lung cancer "susceptibility locus"¯ on chromosome 6, and evidence of a susceptibility region on three other chromosomes. The region of the original chromosome where the lung cancer markers were found contained about 100 genes, including several genes suspected to be involved in tumor suppression and cell growth. Using a genetically altered mouse model, researchers determined that when RGS17 was suppressed, lung tumors shrank, proving the gene was involved in cancer development and must be present for cancer growth. "What was most interesting is that this same gene was over-expressed in 60 percent of the samples from non-hereditary lung tumors,"¯ explains Anderson. "This suggests that perhaps epigenetic factors may be contributing to abnormal genetic development."¯ The UC-led team will conduct additional research to investigate how environmental factors may influence familial cancer development. Funding for this research comes from the National Institutes of Health through the Genetic Epidemiology of Lung Cancer Consortium, a collaborative research effort established in 1997 to research the genetic origins of familial lung cancers. Anderson serves as principal investigator. Collaborating institutions include Washington University-St. Louis, Mayo Clinic-Rochester, University of Colorado, University of Texas Southwestern Medical Center, Louisiana State University, Saccomanno Research Institute, National Cancer Institute, National Human Genome Research Institute, Karmanos Cancer Institute, University of Toledo and M.D. Anderson Cancer Center-Houston. University of Cincinnati |
|||||||||||||||||||||
| Related Lung Cancer Current Events and Lung Cancer News Articles Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Intervals between lung cancer diagnosis and treatment displays a health care disparity Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Experts issue call to reconsider screening for breast cancer and prostate cancer Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association." Detecting the undetectable in prostate cancer screening A team of Northwestern University researchers, using an extremely sensitive tool based on nanotechnology, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation. African American lung cancer patients may have different response to new cancer-fighting drugs Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. More Lung Cancer Current Events and Lung Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||